Comparative Pharmacology
Head-to-head clinical analysis: TESTODERM versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTODERM versus VIRILON.
TESTODERM vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy: binds to androgen receptors, activating gene transcription for protein synthesis and muscle growth.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
One to two 2.5 mg or 5 mg patches applied to clean, dry, intact skin of the back, abdomen, upper arms, or thighs once daily (approximately every 24 hours).
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life is approximately 10-100 minutes for free testosterone in plasma; for total testosterone (including bound), the apparent half-life ranges from 2-4 hours after transdermal application, with significant interindividual variability.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates, <10% as unchanged testosterone); about 6% is excreted in feces via biliary elimination.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen
Androgen